Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers
A latent nigrostriatal deficit and its possible clinical consequences in asymptomatic heterozygous Parkin and PINK1 mutation carriers (AMC) have been a matter of investigation in recent years. Notably, mild Parkinsonian signs in heterozygous mutation carriers can be so subtle that they may be missed...
Gespeichert in:
Veröffentlicht in: | Parkinsonism & related disorders 2017-09, Vol.42, p.95-99 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 99 |
---|---|
container_issue | |
container_start_page | 95 |
container_title | Parkinsonism & related disorders |
container_volume | 42 |
creator | Weissbach, Anne König, Inke R. Hückelheim, Katja Pramstaller, Peter P. Werner, Elisa Brüggemann, Norbert Tadic, Vera Lohmann, Katja Bäumer, Tobias Münchau, Alexander Kasten, Meike Klein, Christine |
description | A latent nigrostriatal deficit and its possible clinical consequences in asymptomatic heterozygous Parkin and PINK1 mutation carriers (AMC) have been a matter of investigation in recent years. Notably, mild Parkinsonian signs in heterozygous mutation carriers can be so subtle that they may be missed if not specifically investigated.
We studied 15 heterozygous Parkin and PINK1 AMC and 18 age- and sex-matched mutation-negative controls using a standardized video, instructing the probands to perform relevant parts of the UPDRS III to investigate fine motor movements at baseline and after first-time L-Dopa administration. Additionally, available UPDRS III scores of mutation carriers from the past ten years were reviewed.
AMC showed a reduced number of fine motor movements per second compared to controls at baseline (p = 0.04). L-Dopa improved motor performance numerically but non-significantly in AMC (p = 0.2301), but significantly in healthy controls (p = 6.1·10–5). Although none of the AMC reported symptoms, nine showed rigidity, bradykinesia, tremor, and postural instability when the UPDRS III was applied. Mean UPDRSIII scores significantly decreased after L-Dopa administration (p = 0.005), but did not increase over the past ten years.
(i) Heterozygous AMC show subtle motor abnormalities when a detailed, specialized motor examination is applied and compared to mutation-negative matched control subjects. (ii) The mild motor deficit present in a subgroup of heterozygous Parkin and PINK1 AMC appears to be non-progressive and responsive to L-dopa administration. (iii) Evaluating motor changes, their progression, and treatment response in AMC can provide valuable insights into possible early disease stages and compensatory mechanisms.
•Parkin/PINK1 AMC show subtle motor abnormalities in specialized motor examination.•This motor deficit appears to be non-progressive and responsive to L-dopa administration.•Motor changes of AMC provide insights into early disease stages and compensatory mechanisms. |
doi_str_mv | 10.1016/j.parkreldis.2017.07.003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1921133150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1353802017302365</els_id><sourcerecordid>1921133150</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-ee113dd4ac5e21ff4b7c622232de82ec682e5938cb2d85f76eff8eb23a709dd53</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EglL4BeQlmxQ_mjhdAuJRUUEXsESWY4-LSxIXO0EqX4-rFlgijTxe3Dt35iCEKRlRQouL5WilwnuA2rg4YoSKEUlF-B4a0FLwLKes2E9_nvOsJIwcoeMYl4QQkRN-iI5YKWgxZmKAXqetrXtoNWBv8SwzfqWwb3Hsq64G3PjOBxzdoo3YtfgNOgj-a73wfcTztIJrM6xag-fTxweKm75TnUturUJwEOIJOrCqjnC660P0cnvzfH2fzZ7upteXs0xzMe4yAEq5MWOlc2DU2nEldMEY48xAyUAX6cknvNQVM2VuRQHWllAxrgSZGJPzITrfzl0F_9FD7GTjooa6Vi2kVSWdsJTAabp-iMqtVAcfYwArV8E1KqwlJXIDVy7lH1y5gStJKsKT9WyX0lcNmF_jD80kuNoKIN36mQDIqN2GrXEBdCeNd_-nfAO3H5EP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1921133150</pqid></control><display><type>article</type><title>Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Weissbach, Anne ; König, Inke R. ; Hückelheim, Katja ; Pramstaller, Peter P. ; Werner, Elisa ; Brüggemann, Norbert ; Tadic, Vera ; Lohmann, Katja ; Bäumer, Tobias ; Münchau, Alexander ; Kasten, Meike ; Klein, Christine</creator><creatorcontrib>Weissbach, Anne ; König, Inke R. ; Hückelheim, Katja ; Pramstaller, Peter P. ; Werner, Elisa ; Brüggemann, Norbert ; Tadic, Vera ; Lohmann, Katja ; Bäumer, Tobias ; Münchau, Alexander ; Kasten, Meike ; Klein, Christine</creatorcontrib><description>A latent nigrostriatal deficit and its possible clinical consequences in asymptomatic heterozygous Parkin and PINK1 mutation carriers (AMC) have been a matter of investigation in recent years. Notably, mild Parkinsonian signs in heterozygous mutation carriers can be so subtle that they may be missed if not specifically investigated.
We studied 15 heterozygous Parkin and PINK1 AMC and 18 age- and sex-matched mutation-negative controls using a standardized video, instructing the probands to perform relevant parts of the UPDRS III to investigate fine motor movements at baseline and after first-time L-Dopa administration. Additionally, available UPDRS III scores of mutation carriers from the past ten years were reviewed.
AMC showed a reduced number of fine motor movements per second compared to controls at baseline (p = 0.04). L-Dopa improved motor performance numerically but non-significantly in AMC (p = 0.2301), but significantly in healthy controls (p = 6.1·10–5). Although none of the AMC reported symptoms, nine showed rigidity, bradykinesia, tremor, and postural instability when the UPDRS III was applied. Mean UPDRSIII scores significantly decreased after L-Dopa administration (p = 0.005), but did not increase over the past ten years.
(i) Heterozygous AMC show subtle motor abnormalities when a detailed, specialized motor examination is applied and compared to mutation-negative matched control subjects. (ii) The mild motor deficit present in a subgroup of heterozygous Parkin and PINK1 AMC appears to be non-progressive and responsive to L-dopa administration. (iii) Evaluating motor changes, their progression, and treatment response in AMC can provide valuable insights into possible early disease stages and compensatory mechanisms.
•Parkin/PINK1 AMC show subtle motor abnormalities in specialized motor examination.•This motor deficit appears to be non-progressive and responsive to L-dopa administration.•Motor changes of AMC provide insights into early disease stages and compensatory mechanisms.</description><identifier>ISSN: 1353-8020</identifier><identifier>EISSN: 1873-5126</identifier><identifier>DOI: 10.1016/j.parkreldis.2017.07.003</identifier><identifier>PMID: 28716427</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Case-Control Studies ; Female ; Genetics ; Heterozygote ; Heterozygous ; Humans ; Levodopa - therapeutic use ; Male ; Middle Aged ; Movement - drug effects ; Mutation - genetics ; Parkinson Disease - drug therapy ; Parkinson Disease - genetics ; Parkinsonism ; Pharmacogenomic Testing ; Protein Kinases - genetics ; Rating scales ; Statistics, Nonparametric ; Ubiquitin-Protein Ligases - genetics</subject><ispartof>Parkinsonism & related disorders, 2017-09, Vol.42, p.95-99</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-ee113dd4ac5e21ff4b7c622232de82ec682e5938cb2d85f76eff8eb23a709dd53</citedby><cites>FETCH-LOGICAL-c374t-ee113dd4ac5e21ff4b7c622232de82ec682e5938cb2d85f76eff8eb23a709dd53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.parkreldis.2017.07.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28716427$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weissbach, Anne</creatorcontrib><creatorcontrib>König, Inke R.</creatorcontrib><creatorcontrib>Hückelheim, Katja</creatorcontrib><creatorcontrib>Pramstaller, Peter P.</creatorcontrib><creatorcontrib>Werner, Elisa</creatorcontrib><creatorcontrib>Brüggemann, Norbert</creatorcontrib><creatorcontrib>Tadic, Vera</creatorcontrib><creatorcontrib>Lohmann, Katja</creatorcontrib><creatorcontrib>Bäumer, Tobias</creatorcontrib><creatorcontrib>Münchau, Alexander</creatorcontrib><creatorcontrib>Kasten, Meike</creatorcontrib><creatorcontrib>Klein, Christine</creatorcontrib><title>Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers</title><title>Parkinsonism & related disorders</title><addtitle>Parkinsonism Relat Disord</addtitle><description>A latent nigrostriatal deficit and its possible clinical consequences in asymptomatic heterozygous Parkin and PINK1 mutation carriers (AMC) have been a matter of investigation in recent years. Notably, mild Parkinsonian signs in heterozygous mutation carriers can be so subtle that they may be missed if not specifically investigated.
We studied 15 heterozygous Parkin and PINK1 AMC and 18 age- and sex-matched mutation-negative controls using a standardized video, instructing the probands to perform relevant parts of the UPDRS III to investigate fine motor movements at baseline and after first-time L-Dopa administration. Additionally, available UPDRS III scores of mutation carriers from the past ten years were reviewed.
AMC showed a reduced number of fine motor movements per second compared to controls at baseline (p = 0.04). L-Dopa improved motor performance numerically but non-significantly in AMC (p = 0.2301), but significantly in healthy controls (p = 6.1·10–5). Although none of the AMC reported symptoms, nine showed rigidity, bradykinesia, tremor, and postural instability when the UPDRS III was applied. Mean UPDRSIII scores significantly decreased after L-Dopa administration (p = 0.005), but did not increase over the past ten years.
(i) Heterozygous AMC show subtle motor abnormalities when a detailed, specialized motor examination is applied and compared to mutation-negative matched control subjects. (ii) The mild motor deficit present in a subgroup of heterozygous Parkin and PINK1 AMC appears to be non-progressive and responsive to L-dopa administration. (iii) Evaluating motor changes, their progression, and treatment response in AMC can provide valuable insights into possible early disease stages and compensatory mechanisms.
•Parkin/PINK1 AMC show subtle motor abnormalities in specialized motor examination.•This motor deficit appears to be non-progressive and responsive to L-dopa administration.•Motor changes of AMC provide insights into early disease stages and compensatory mechanisms.</description><subject>Case-Control Studies</subject><subject>Female</subject><subject>Genetics</subject><subject>Heterozygote</subject><subject>Heterozygous</subject><subject>Humans</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Movement - drug effects</subject><subject>Mutation - genetics</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - genetics</subject><subject>Parkinsonism</subject><subject>Pharmacogenomic Testing</subject><subject>Protein Kinases - genetics</subject><subject>Rating scales</subject><subject>Statistics, Nonparametric</subject><subject>Ubiquitin-Protein Ligases - genetics</subject><issn>1353-8020</issn><issn>1873-5126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EglL4BeQlmxQ_mjhdAuJRUUEXsESWY4-LSxIXO0EqX4-rFlgijTxe3Dt35iCEKRlRQouL5WilwnuA2rg4YoSKEUlF-B4a0FLwLKes2E9_nvOsJIwcoeMYl4QQkRN-iI5YKWgxZmKAXqetrXtoNWBv8SwzfqWwb3Hsq64G3PjOBxzdoo3YtfgNOgj-a73wfcTztIJrM6xag-fTxweKm75TnUturUJwEOIJOrCqjnC660P0cnvzfH2fzZ7upteXs0xzMe4yAEq5MWOlc2DU2nEldMEY48xAyUAX6cknvNQVM2VuRQHWllAxrgSZGJPzITrfzl0F_9FD7GTjooa6Vi2kVSWdsJTAabp-iMqtVAcfYwArV8E1KqwlJXIDVy7lH1y5gStJKsKT9WyX0lcNmF_jD80kuNoKIN36mQDIqN2GrXEBdCeNd_-nfAO3H5EP</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Weissbach, Anne</creator><creator>König, Inke R.</creator><creator>Hückelheim, Katja</creator><creator>Pramstaller, Peter P.</creator><creator>Werner, Elisa</creator><creator>Brüggemann, Norbert</creator><creator>Tadic, Vera</creator><creator>Lohmann, Katja</creator><creator>Bäumer, Tobias</creator><creator>Münchau, Alexander</creator><creator>Kasten, Meike</creator><creator>Klein, Christine</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201709</creationdate><title>Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers</title><author>Weissbach, Anne ; König, Inke R. ; Hückelheim, Katja ; Pramstaller, Peter P. ; Werner, Elisa ; Brüggemann, Norbert ; Tadic, Vera ; Lohmann, Katja ; Bäumer, Tobias ; Münchau, Alexander ; Kasten, Meike ; Klein, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-ee113dd4ac5e21ff4b7c622232de82ec682e5938cb2d85f76eff8eb23a709dd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Case-Control Studies</topic><topic>Female</topic><topic>Genetics</topic><topic>Heterozygote</topic><topic>Heterozygous</topic><topic>Humans</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Movement - drug effects</topic><topic>Mutation - genetics</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - genetics</topic><topic>Parkinsonism</topic><topic>Pharmacogenomic Testing</topic><topic>Protein Kinases - genetics</topic><topic>Rating scales</topic><topic>Statistics, Nonparametric</topic><topic>Ubiquitin-Protein Ligases - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weissbach, Anne</creatorcontrib><creatorcontrib>König, Inke R.</creatorcontrib><creatorcontrib>Hückelheim, Katja</creatorcontrib><creatorcontrib>Pramstaller, Peter P.</creatorcontrib><creatorcontrib>Werner, Elisa</creatorcontrib><creatorcontrib>Brüggemann, Norbert</creatorcontrib><creatorcontrib>Tadic, Vera</creatorcontrib><creatorcontrib>Lohmann, Katja</creatorcontrib><creatorcontrib>Bäumer, Tobias</creatorcontrib><creatorcontrib>Münchau, Alexander</creatorcontrib><creatorcontrib>Kasten, Meike</creatorcontrib><creatorcontrib>Klein, Christine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Parkinsonism & related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weissbach, Anne</au><au>König, Inke R.</au><au>Hückelheim, Katja</au><au>Pramstaller, Peter P.</au><au>Werner, Elisa</au><au>Brüggemann, Norbert</au><au>Tadic, Vera</au><au>Lohmann, Katja</au><au>Bäumer, Tobias</au><au>Münchau, Alexander</au><au>Kasten, Meike</au><au>Klein, Christine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers</atitle><jtitle>Parkinsonism & related disorders</jtitle><addtitle>Parkinsonism Relat Disord</addtitle><date>2017-09</date><risdate>2017</risdate><volume>42</volume><spage>95</spage><epage>99</epage><pages>95-99</pages><issn>1353-8020</issn><eissn>1873-5126</eissn><abstract>A latent nigrostriatal deficit and its possible clinical consequences in asymptomatic heterozygous Parkin and PINK1 mutation carriers (AMC) have been a matter of investigation in recent years. Notably, mild Parkinsonian signs in heterozygous mutation carriers can be so subtle that they may be missed if not specifically investigated.
We studied 15 heterozygous Parkin and PINK1 AMC and 18 age- and sex-matched mutation-negative controls using a standardized video, instructing the probands to perform relevant parts of the UPDRS III to investigate fine motor movements at baseline and after first-time L-Dopa administration. Additionally, available UPDRS III scores of mutation carriers from the past ten years were reviewed.
AMC showed a reduced number of fine motor movements per second compared to controls at baseline (p = 0.04). L-Dopa improved motor performance numerically but non-significantly in AMC (p = 0.2301), but significantly in healthy controls (p = 6.1·10–5). Although none of the AMC reported symptoms, nine showed rigidity, bradykinesia, tremor, and postural instability when the UPDRS III was applied. Mean UPDRSIII scores significantly decreased after L-Dopa administration (p = 0.005), but did not increase over the past ten years.
(i) Heterozygous AMC show subtle motor abnormalities when a detailed, specialized motor examination is applied and compared to mutation-negative matched control subjects. (ii) The mild motor deficit present in a subgroup of heterozygous Parkin and PINK1 AMC appears to be non-progressive and responsive to L-dopa administration. (iii) Evaluating motor changes, their progression, and treatment response in AMC can provide valuable insights into possible early disease stages and compensatory mechanisms.
•Parkin/PINK1 AMC show subtle motor abnormalities in specialized motor examination.•This motor deficit appears to be non-progressive and responsive to L-dopa administration.•Motor changes of AMC provide insights into early disease stages and compensatory mechanisms.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28716427</pmid><doi>10.1016/j.parkreldis.2017.07.003</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1353-8020 |
ispartof | Parkinsonism & related disorders, 2017-09, Vol.42, p.95-99 |
issn | 1353-8020 1873-5126 |
language | eng |
recordid | cdi_proquest_miscellaneous_1921133150 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Case-Control Studies Female Genetics Heterozygote Heterozygous Humans Levodopa - therapeutic use Male Middle Aged Movement - drug effects Mutation - genetics Parkinson Disease - drug therapy Parkinson Disease - genetics Parkinsonism Pharmacogenomic Testing Protein Kinases - genetics Rating scales Statistics, Nonparametric Ubiquitin-Protein Ligases - genetics |
title | Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A35%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20L-dopa%20on%20subtle%20motor%20signs%20in%20heterozygous%20Parkin-%20and%20PINK1%20mutation%20carriers&rft.jtitle=Parkinsonism%20&%20related%20disorders&rft.au=Weissbach,%20Anne&rft.date=2017-09&rft.volume=42&rft.spage=95&rft.epage=99&rft.pages=95-99&rft.issn=1353-8020&rft.eissn=1873-5126&rft_id=info:doi/10.1016/j.parkreldis.2017.07.003&rft_dat=%3Cproquest_cross%3E1921133150%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1921133150&rft_id=info:pmid/28716427&rft_els_id=S1353802017302365&rfr_iscdi=true |